Harnessing the beneficial properties of adipogenic microbes for improving human health
Summary Obesity is associated with numerous metabolic comorbidities. Weight loss is an effective measure for alleviating many of these metabolic abnormalities. However, considering the limited success of most medical weight‐management approaches in producing a sustained weight loss, approaches that...
Saved in:
Published in | Obesity reviews Vol. 14; no. 9; pp. 721 - 735 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.09.2013
Wiley Subscription Services, Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Obesity is associated with numerous metabolic comorbidities. Weight loss is an effective measure for alleviating many of these metabolic abnormalities. However, considering the limited success of most medical weight‐management approaches in producing a sustained weight loss, approaches that improve obesity‐related metabolic abnormalities independent of weight loss would be extremely attractive and of practical benefit. Metabolically healthy obesity supports the notion that a better metabolic profile is possible despite obesity. Moreover, adequate expansion of adipose tissue appears to confer protection from obesity‐induced metabolic comorbidities. To this end, the 10th Stock conference examined new approaches to improve metabolic comorbidities independent of weight loss. In particular, human adenovirus 36 (Ad36) and specific gut microbes were examined for their potential to influence lipid and glucose homeostasis in animals and humans. While these microbes possess some undesirable properties, research has identified attributes of adenovirus Ad36 and gut microbes that may be selectively harnessed to improve metabolic profile without the obligatory weight loss. Furthermore, identifying the host signalling pathways that these microbes recruit to improve the metabolic profile may offer new templates and targets, which may facilitate the development of novel treatment strategies for obesity‐related metabolic conditions. |
---|---|
Bibliography: | Vital Health Interventions, LLC Nutricia Research Foundation istex:45B7D61A886B3E24F5D1A40C91783EBC0CD14998 ark:/67375/WNG-SGRDBFC5-6 Ministry of Education, Science and Technology - No. 2012039819 SFD (Société Francophone du Diabète, France) FRSM (Fonds de la Recherche Scientifique Médicale, Belgium) ArticleID:OBR12045 ARC (Action de Recherche Concertée) FSR (fonds spéciaux de recherche, Université catholique de Louvain, Belgium) Patent filed November 2006. File no. 05P09. Adenovirus Ad36 E4orf1 protein for prevention and treatment of non‐alcoholic fatty liver disease. U.S. patent application 8 July 2010. 61/362,443; Taiwan. Patent number 100124173. Enhanced glycaemic control using Ad36E4orf1 and AKT1 Inhibitor. January 2013. Dhurandhar NV and Holland TC. Ad‐36 E4 orf‐1, E1A and obesity and diabetes. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Feature-3 ObjectType-Review-1 |
ISSN: | 1467-7881 1467-789X |
DOI: | 10.1111/obr.12045 |